PMID- 36153872
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20220928
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 102
IP  - 36
DP  - 2022 Sep 27
TI  - [Clinical characteristics and prognosis of patients with newly-diagnosed multiple 
      myeloma with t(11;14)].
PG  - 2868-2873
LID - 10.3760/cma.j.cn112137-20211229-02917 [doi]
AB  - Objective: To explore the clinical characteristics and prognosis of multiple 
      myeloma (MM) patients with t(11;14). Methods: The clinical data of patients newly 
      diagnosed with MM with t(11;14), which confirmed by fluorescence in situ 
      hybridization (FISH), from January 1, 2016 to May 31, 2021 in Ruijin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine was 
      retrospectively collected. A total of 45 patients were included. Bortezomib based 
      induction therapy were given to 88.9% (40/45) patients, while 11.1% (5/45) 
      received Imids-based therapy. Fourteen patients underwent the autologous 
      hematopoietic stem cell transplantation (AHSCT). The clinical characteristics, 
      overall response rate (ORR), progression free survival (PFS), overall survival 
      (OS) and risk factors affecting survival were analyzed. Results: The average age 
      of patients were (58.8+/-9.6) years, and 62.2%(28/45)were male. A relatively high 
      incidence of bone lesion 82.2%(37/45)was observed. After 4 cycles induction 
      therapy, the ORR was 66.7% (30/45), and >/=very good partial response (VGPR) was 
      31.3% (14/45). The rate of >/=VGPR increased to 92.9% (13/14) after AHSCT. The 
      follow-up time [M(Q(1),Q(3))] was 27(20,42)months. The PFS was 34 (95%CI: 23-45) 
      months, the median OS was 44 (95%CI:33-51) months. Median PFS were 48 (only 3 
      cases of progressive disease, CI not available) months and 24 (95%CI:13-35) 
      months in the transplantation group and non-transplant group respectively 
      (P=0.115). Median OS were 60 (only 1 case of death, CI not available) months and 
      48 (95%CI:22-74) months in the transplantation group and non-transplantation 
      group, respectively (P=0.238). Cox regression analysis indicated that the number 
      of plasma cell >/=50% in bone marrow and CD20 expression on myeloma cells were the 
      risk factors for 
      PFS[OR=3.272,95%CI:1.167-9.170,P=0.024;OR=3.480,95%CI:1.082-11.234,P=0.036]. No 
      significant effective factor on OS was found. Conclusions: For multiple myeloma 
      patient with t(11;14), the response rate with novel agents induction therapy is 
      not high, but autologous stem cell transplantation can deepen remission. The high 
      burden of bone marrow plasma cells and the expression of CD20 may be associated 
      with the poor prognosis.
FAU - Wang, Y
AU  - Wang Y
AD  - Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai Institute of Hematology, State Key 
      Laboratory of Medical Genomics, National Research Center for Translational 
      Medicine at Shanghai, Shanghai 200025, China.
FAU - Liu, Y F
AU  - Liu YF
AD  - Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai Institute of Hematology, State Key 
      Laboratory of Medical Genomics, National Research Center for Translational 
      Medicine at Shanghai, Shanghai 200025, China.
FAU - Tao, Y
AU  - Tao Y
AD  - Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai Institute of Hematology, State Key 
      Laboratory of Medical Genomics, National Research Center for Translational 
      Medicine at Shanghai, Shanghai 200025, China.
FAU - Jin, S W
AU  - Jin SW
AD  - Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai Institute of Hematology, State Key 
      Laboratory of Medical Genomics, National Research Center for Translational 
      Medicine at Shanghai, Shanghai 200025, China.
FAU - Mi, J Q
AU  - Mi JQ
AD  - Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai Institute of Hematology, State Key 
      Laboratory of Medical Genomics, National Research Center for Translational 
      Medicine at Shanghai, Shanghai 200025, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bortezomib
MH  - China
MH  - Disease-Free Survival
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - *Multiple Myeloma/diagnosis/drug therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2022/09/27 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/09/26 03:48
PHST- 2022/09/26 03:48 [entrez]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
AID - 10.3760/cma.j.cn112137-20211229-02917 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2022 Sep 27;102(36):2868-2873. doi: 
      10.3760/cma.j.cn112137-20211229-02917.